Apr 29, 2020

HRIBO - High-throughput analysis of bacterial ribosome profiling data

BioRxiv : the Preprint Server for Biology
R. GelhausenRolf Backofen

Abstract

Motivation: Ribosome profiling (Ribo-seq) is a powerful approach based on ribosome-protected RNA fragments to explore the translatome of a cell, and is especially useful for the detection of small proteins (<=70 amino acids) that are recalcitrant to biochemical and in silico approaches. While pipelines are available to analyze Ribo-seq data, none are designed explicitly for the analysis of Ribo-seq data from prokaryotes, nor are they focused on the discovery of unannotated open reading frames (ORFs) in bacteria. Results: We present HRIBO (High-throughput annotation by Ribo-seq), a workflow to enable reproducible and high-throughput analysis of bacterial Ribo-seq data. The workflow performs all required pre-processing and quality control steps. Importantly, HRIBO outputs annotation-independent ORF predictions based on two complementary bacteria-focused tools, and integrates them with additional features. This facilitates the rapid discovery of novel ORFs and their prioritization for functional characterization. Availability: HRIBO is a free and open source project available under the GPL-3 license at: https://github.com/RickGelhausen/HRIBO .

  • References
  • Citations

References

  • We're still populating references for this paper, please check back later.
  • References
  • Citations

Citations

  • This paper may not have been cited yet.

Mentioned in this Paper

Biological Neural Networks
2,19-(methyleneoxy)androst-4-ene-3,17-dione
Research
Drug Delivery Systems
Classification
Adverse Effects
Pharmacologic Substance
Mechanical Ingredient
High Throughput Analysis
Pharmacogenomics

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.